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Leiden University Medical Center, Dept. of Clinical Pharmacy & Toxicology, Leiden, The NetherlandsPharmacogenetics is one of the first clinical applications ofthe postgenomic era; it studies the role of heritability of drug
responses. It promises personalised medicine rather than the
established ‘one size fits all’ approach to drugs and dosages.
This should ultimately lead to more efficient and safer drug
therapy. In recent years, pharmacogenetic information has
been included in drug labels (especially for oncology drugs),
and commercially available pharmacogenetic tests have been
approved by the Food and Drug Administration (FDA), but
their application in routine patient care remains limited. In-
deed, the implementation of pharmacogenetics in routine
clinical practice presents significant challenges. The clinical
value and the interpretation of pharmacogenetic tests are
found difficult. Now, pharmacogenetics-based therapeutic
(dose) recommendations, based upon the systematic review
of the literature, are available for 53 drugs associated withgenes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-
methyltransferase (TPMT), dihydropyrimidine dehydrogenase
(DPD), vitamin K epoxide reductase (VKORC1), uridine
diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-
B44, HLA-B*5701, CYP3A5 and factor V Leiden (FVL). These
two large initiatives are made available through the pharmac-
ogenomics knowledge base and may help clinicians to make
use of current pharmacogenetic knowledge. In the teaching
lecture specific clinical examples of challenges for implemen-
tation of pharmacogenetics are discussed, and best practices
for implementation will be presented.
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